Found 10 search result(s) for Gilead.
Triangle Pharmaceuticals
(HIV/AIDS Research: Its History & Future Meeting)
... Triangle Pharmaceuticals developed FTC (emtricitabine), and was acquired by Gilead in 2003
Jan 11, 2021
... Triangle Pharmaceuticals developed FTC (emtricitabine), and was acquired by Gilead in 2003
Jan 11, 2021
elvitegravir (EVG)
(HIV/AIDS Research: Its History & Future Meeting)
... Elvitegravir (EVG) is an integrase inhibitor developed by Gilead, and approved by the FDA in 2012. It is most commonly administered in combination with cobicistat, FTC (emtricitabine ...
Jan 18, 2021
... Elvitegravir (EVG) is an integrase inhibitor developed by Gilead, and approved by the FDA in 2012. It is most commonly administered in combination with cobicistat, FTC (emtricitabine ...
Jan 18, 2021
6.7 Salim Abdool Karim — Stopping the Spread of HIV in Developing Countries
(HIV/AIDS Research: Its History & Future Meeting)
... understand how we could contribute and what is it we could do? Working with Gilead and developing an approach to using tenofovir gel, we decided to design a study to look ...
Apr 27, 2021
... understand how we could contribute and what is it we could do? Working with Gilead and developing an approach to using tenofovir gel, we decided to design a study to look ...
Apr 27, 2021
3.6 John C. Martin — Making it Simpler: A Single Pill to Treat HIV
(HIV/AIDS Research: Its History & Future Meeting)
... John C. Martin (b. 1951) is a medicinal chemist, and former chairman and CEO of Gilead Sciences. Jump to: Q&A Citations Index Search Video http://library.cshl.edu/Meetings/HIVAIDS/videopages/Martin.php We switched ...
Apr 27, 2021
... John C. Martin (b. 1951) is a medicinal chemist, and former chairman and CEO of Gilead Sciences. Jump to: Q&A Citations Index Search Video http://library.cshl.edu/Meetings/HIVAIDS/videopages/Martin.php We switched ...
Apr 27, 2021
3.3 Douglas Richman: Antiviral Drug Resistance and Combination ART
(HIV/AIDS Research: Its History & Future Meeting)
... where the treatment was expanding. The availability of dolutegravir (DTG, Tivicay) and the 00:27:30 Gilead integrase inhibitor you'll hear about, plus the availability of TAF (tenofovir alafenamide ...
Apr 27, 2021
... where the treatment was expanding. The availability of dolutegravir (DTG, Tivicay) and the 00:27:30 Gilead integrase inhibitor you'll hear about, plus the availability of TAF (tenofovir alafenamide ...
Apr 27, 2021
6.1 Sharon Hillier — Development and Application of Pre-exposure Prophylaxis (PrEP)
(HIV/AIDS Research: Its History & Future Meeting)
... incidence is in excess of 3% per year. (15) That has led to a huge movement by Gilead, and I think they are to be recognized for the great work they've done in trying to get regulatory ...
Apr 27, 2021
... incidence is in excess of 3% per year. (15) That has led to a huge movement by Gilead, and I think they are to be recognized for the great work they've done in trying to get regulatory ...
Apr 27, 2021
Session 10: What Have We Learned?
(HIV/AIDS Research: Its History & Future Meeting)
... do it. Can’t you just go to a drug company or someone like that, like Gilead and just say, “We want a book and 00:40:30 you’ll be properly ...
Apr 27, 2021
... do it. Can’t you just go to a drug company or someone like that, like Gilead and just say, “We want a book and 00:40:30 you’ll be properly ...
Apr 27, 2021
8.5 Sharon Lewin — Research to a Cure: A Possible Goal?
(HIV/AIDS Research: Its History & Future Meeting)
... reversal. Many epigenetic modifiers, the TLR agonists, specifically TLR7 agonists developed by Gilead look very promising. Activators of NFκB, we've heard of bryostatin and also ingenol ...
Apr 27, 2021
... reversal. Many epigenetic modifiers, the TLR agonists, specifically TLR7 agonists developed by Gilead look very promising. Activators of NFκB, we've heard of bryostatin and also ingenol ...
Apr 27, 2021
Session 7: Prospects for an HIV Vaccine
(HIV/AIDS Research: Its History & Future Meeting)
... There's a positive economic model and we can speak with our colleagues from Gilead, but you can't get this reimbursed, you can make it profitable. That's the best ...
Apr 27, 2021
... There's a positive economic model and we can speak with our colleagues from Gilead, but you can't get this reimbursed, you can make it profitable. That's the best ...
Apr 27, 2021
3.4 Raymond Schinazi — Discovery and Development of Novel NRTIs
(HIV/AIDS Research: Its History & Future Meeting)
... Burroughs Wellcome back to Emory back to Triangle Pharmaceuticals and eventually ended up with Gilead. That's the path, a very complicated path. 00:20:30 There's been ...
Apr 27, 2021
... Burroughs Wellcome back to Emory back to Triangle Pharmaceuticals and eventually ended up with Gilead. That's the path, a very complicated path. 00:20:30 There's been ...
Apr 27, 2021